Meeting
2018 Gastrointestinal Cancers Symposium
Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC).
Authors
Antoine Hollebecque
Gustave Roussy Cancer Institute, Villejuif, France
Antoine Hollebecque , Aitana Calvo , Thierry Andre , Guillem Argiles , Andres Cervantes , Catherine Leger , Aude Valette , Nadia Amellal , Ronan Fougeray , Josep Tabernero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02848443
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 816)
DOI
10.1200/JCO.2018.36.4_suppl.816
Abstract #
816
Poster Bd #
M15
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in metastatic colorectal cancer.
First Author: Antoine Hollebecque
Poster
2020 Gastrointestinal Cancers Symposium
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab: Results of the expansion part of a phase I study in patients with metastatic colorectal cancer.
First Author: Roberto Bordonaro
Poster
2018 ASCO Annual Meeting
A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC).
First Author: Anna M. Varghese
Poster
2014 Gastrointestinal Cancers Symposium
A phase I/II study of cetuximab (cet) in combination with S-1 and oxaliplatin (SOX) in first-line treatment for metastatic colorectal cancer (mCRC) (JACCRO CC-06).
First Author: Akihito Tsuji